Minutes of the June 12, 2009
Pharmacy & Therapeutics (P&T) Committee Meeting
SD Department of Social Services, Medical Services Division

Members present
Dana Darger, R.Ph.; Verdayne Brandenburg, M.D.; Bill Ladwig, R.Ph.; Dennis Hedge, PharmD.; Rick Holm, M.D.; Debra Farver, PharmD.; James Engelbrecht, M.D.

Members absent
Willis Sutliff, M.D.; Galen Goeden, R.Ph.; Timothy Soundy, M.D.

DSS staff present
Mike Jockheck, R.Ph.

HID staff present
Candace Rieth, Pharm.D.

Administrative Business
The P&T meeting was called to order by D. Darger at approximately 1:10pm. The minutes of the March 13, 2009 meeting were presented. B. Ladwig made a motion to approve as written, with a second by D. Farver. The motion was approved unanimously.

Prior Authorization Statistics
C. Rieth presented an overview of the prior authorization (PA) activity for April 2009. There were a total of 1,781 PAs processed in the month of April, with 99.89% of those requests responded to in less than 8 hours. There were 1,482 (83%) requests received electronically and 299 (17%) requests received by fax. In response to a request from the committee, C. Rieth presented the number of approvals and denials, by form type, for the faxed (manual) PA requests.

Analysis of the Top 15 Therapeutic Classes
C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 01/01/2009 – 03/25/2009. The top five classes were antipsychotics, anticonvulsants, cerebral stimulants, amphetamines, and beta-adrenergic agonists. The top 15 therapeutic classes make up 46.57% of total claims.

Antipsychotic/Antidepressant/Xopenex Mailing
M. Jockheck gave an update on the mailings. The antidepressant mailing is in the final approval stages. The Xopenex and antipsychotic mailings are still being drafted. The committee will be notified when these letters are mailed.

Targeted Immunomodulator Review
C. Rieth reviewed targeted immunomodulators with the P&T committee. Pam Sardo spoke on behalf of Abbott, manufacturer of Humira. Joan Houska spoke on behalf of Centocor, manufacturer of Remicade and Simponi. B. Ladwig made a motion to place targeted

immunomodulators on prior authorization. V. Brandenburg seconded the motion. The motion was approved unanimously. Prior authorization criteria will be drafted for the September meeting. The committee also asked that utilization of the immunomodulators billed through the medical claims process be provided for the September meeting.

Moxatag Review

C. Rieth reviewed Moxatag with the P&T committee. There was no public comment. B. Ladwig made a motion to place Moxatag on prior authorization immediately. D. Farver seconded the motion. The motion was approved unanimously.

Uloric Review

C. Rieth reviewed Uloric with the P&T committee. J. Engelbrecht disclosed that he was on the speaker's bureau for Takeda and that he would recuse himself from the discussion. There was no public comment. B. Ladwig made a motion to place Uloric on prior authorization. V. Brandenburg seconded the motion. The motion was approved with one abstention. Prior authorization criteria and utilization information will be brought to the September meeting.

Bystolic Review

C. Rieth reviewed Bystolic information with the P&T committee. The committee tabled discussion on Bystolic based on the general consensus that Bystolic's mechanism of action is different than the other beta blockers on the market.

Amrix/Fexmid Review

C. Rieth reviewed Amrix and Fexmid with the P&T committee. There was no public comment. B. Ladwig made a motion to place Amrix and Fexmid on prior authorization immediately. D. Farver seconded the motion. The motion was approved unanimously.

The next meeting date is September 11, 2009. The location should remain the same. A motion was made by J. Engelbrecht at 2:25pm to adjourn the SD Medicaid P&T meeting. B. Ladwig seconded. Motion passed unanimously and the meeting was adjourned.